Asciminib Hydrochloride
This page contains brief information about asciminib hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Asciminib hydrochloride is approved to treat adults with:
- chronic myelogenous leukemia (CML) that is in chronic phase and is Philadelphia chromosome positive. It is used:
- in patients who have received at least two tyrosine kinase inhibitors
- in patients whose CML has the T315I mutation
- in patients with newly diagnosed CML¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that asciminib hydrochloride provides a clinical benefit in these patients.
Asciminib hydrochloride is also being studied in the treatment of other types of cancer.
More About Asciminib Hydrochloride
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Asciminib Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.